公开(公告)号：US20250041298A1

公开(公告)日：2025-02-06

申请号：US18714642

申请日：2022-11-29

Applicant: Pfizer Inc. ,  PFIZER INC.

Inventor： Tun Tun Lin ,  Jing Yang

IPC: A61K31/506 ,  A61K31/4196 ,  A61K31/565 ,  A61P35/00

Abstract: The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060 and an endocrine therapy agent.

公开(公告)号：US20250163168A1

公开(公告)日：2025-05-22

申请号：US18947069

申请日：2024-11-14

Applicant: PFIZER INC.

Inventor： James Reasoner APGAR ,  Robert Gregory DULLEA ,  Jean-Philippe FORTIN ,  Allison Nicole LAU ,  Laura LIN LOHSE ,  Weixu MENG ,  Lidia MOSYAK

IPC: C07K16/28 ,  A61K39/00 ,  A61P3/04

Abstract: Disclosed herein are novel antibodies, novel agonist peptides, and novel dual agonist peptides. Further disclosed herein are novel antibody conjugates comprising the novel antibodies, novel agonist peptides, and/or novel dual agonist peptides disclosed herein. In some embodiments, the antibodies or antibody conjugates of the invention may be used to treat metabolic diseases.

公开(公告)号：US20250154270A1

公开(公告)日：2025-05-15

申请号：US18967173

申请日：2024-12-03

Applicant: Pfizer Inc.

Inventor： Manoj Baburao CHARATI ,  Yoon-Chi HAN ,  Madan KATRAGADDA ,  Nicole Melissa PICHÉ-NICHOLAS ,  Lawrence Nathan TUMEY

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C12N15/63

Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).

公开(公告)号：US20250145725A1

公开(公告)日：2025-05-08

申请号：US18919327

申请日：2024-10-17

Applicant: Pfizer Inc.

Inventor： Surabhi Srivatsa Srinivasan ,  Niranjana Aditi Nagarajan ,  Siler Panowski ,  Yoon Park ,  Tao Sai ,  Barbra Johnson Sasu ,  Thomas John Van Blarcom ,  Mathilde Brunnhilde Dusseaux ,  Roman Galetto

IPC: C07K16/28 ,  A61K39/00 ,  A61K40/11 ,  A61K40/31 ,  A61K40/42 ,  A61P35/02 ,  A61P35/04 ,  C07K14/725 ,  C12N5/0783

Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

公开(公告)号：US20250135006A1

公开(公告)日：2025-05-01

申请号：US18763016

申请日：2024-07-03

Applicant: Pfizer Inc.

Inventor： Derek William Bartlett ,  Zoltan Beck ,  Andrew Fensome ,  Mark Edward Flanagan ,  Michael William Pride

IPC: A61K47/22 ,  A61K31/496 ,  A61K39/39 ,  A61K47/28

Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, L, X, Y and p are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may modulate the activity of antigens of interest and may be useful in inducing or enhancing an immune response against diseases, disorders and conditions mediated by antigens of interest.

公开(公告)号：US12281127B2

公开(公告)日：2025-04-22

申请号：US18903345

申请日：2024-10-01

Applicant: PFIZER INC.

Inventor： Benjamin Joseph Burke ,  Jacob Cole Deforest ,  Asako Nagata ,  Simon Paul Planken ,  Jillian Elyse Spangler ,  Scott Channing Sutton ,  Hanna Maria Wisniewska ,  Shouliang Yang

IPC: C07D519/00 ,  A61K31/553 ,  A61P35/00

Abstract: The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.

公开(公告)号：US20250099424A1

公开(公告)日：2025-03-27

申请号：US18917336

申请日：2024-10-16

Applicant: Pfizer Inc.

Inventor： Dafydd Rhys Owen ,  Matthew Richard Reese ,  Matthew Forrest Sammons ,  Jamison Bryce Tuttle ,  Patrick Robert Verhoest ,  Qingyi Yang

IPC: A61K31/403 ,  A61K31/401 ,  A61K31/427 ,  A61P31/14 ,  C07D403/12

Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

公开(公告)号：US20250066337A1

公开(公告)日：2025-02-27

申请号：US18684225

申请日：2022-08-23

Applicant: Pfizer Inc.

Inventor： Kevin Francis DeBoyace ,  Brian Matthew Samas ,  Heather Lynn Frericks Schmidt

IPC: C07D405/14 ,  A61K31/506 ,  A61K45/06

Abstract: Solid forms of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide, including crystalline forms and an amorphous form, in addition to pharmaceutical compositions, processes for preparing, and their use to treat diseases, conditions and disorders modulated by the activity of the diacylglycerol acyltransferase 2 (DGAT2) in a mammal such as a human are described herein.

公开(公告)号：US12227507B2

公开(公告)日：2025-02-18

申请号：US17636510

申请日：2020-08-20

Applicant: Pfizer Inc.

Inventor： George Stuart Cockerill ,  James Good ,  Craig Alex Avery ,  Andrew Joseph Warner ,  Edward James Cochrane

IPC: A61K31/5513 ,  A61K45/06 ,  A61P31/14 ,  C07D487/04 ,  C07D519/00

Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, and are bonds, and and are absent; or (ii) T is C, Z is N, and are bonds, and and are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7, —COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

公开(公告)号：US20250041277A1

公开(公告)日：2025-02-06

申请号：US18715085

申请日：2022-12-01

Applicant: PFIZER INC.

Inventor： Lars ANDERS ,  Jerry LI ,  Tun Tun LIN ,  Ping WEI ,  Jing YANG ,  Todd Lee VANARSDALE

IPC: A61K31/4155 ,  A61K31/4196 ,  A61K31/506 ,  A61K31/565 ,  A61P35/00

Abstract: This disclosure relates to combination therapies for use in treating cancer, comprising a CDK2 inhibitor of Formula (I) and a selective CDK4 inhibitor of Formula (II), each as further described herein, optionally in further combination with an additional anti-cancer agent.